← GLP-1 receptor agonists × cardiovascular events

TrialJAMA cardiology2019

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.

Subodh Verma et al.PubMed ↗Full text ↗Publisher ↗

A secondary analysis of NCT01179048. The trial’s primary report, PMID 27295427, speaks for it on the map; the numbers here are shown and do not vote.

What the trial testedrandomised · 9,340 people · 2019

Randomised comparison

Reduced cardiovascular events

Doesn’t vote: a later paper about the trial

−16%−24% to −7%

Bigger than 3 in 10 for cardiovascular events

As reported

HR 0.84, 95% CI 0.76–0.93

Randomised comparison

Reduced cardiovascular events

Doesn’t vote: a later paper about the trial

−13%−19% to −7%

Bigger than 2 in 10 for cardiovascular events

As reported

HR 0.87, 95% CI 0.81–0.93

Two numbers in the abstract

the abstract, start to end

… in total MACE (hazard ratio [HR], 0.84; 95% CI, 0.76-0.93) and a 13.4% reduction in total expanded MACE (HR, 0.87; 95% CI, 0.81-0.93) compared …

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.840.76–0.93
Cardiovascular events
HR 0.870.81–0.93
GLP-1 receptor agonistsCardiovascular events
1 / 3

29 papers cite it

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01179048phase 39,341 enrolled2010a later paper about it
Full record →Abstract, authors, funding and every citing paper · PMID 31721979